Universal Ibogaine Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Nicholas Peter Karos
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 400 3rd Avenue SW Calgary AB Canada T2P 4H2
- IPO Date
- Mar 1, 2022
- Website
- universalibogaine.com
- Similar Companies
- Business
- Universal Ibogaine Inc. (TSXV: IBO, OTC: IBOGF) develops and commercializes ibogaine-based addiction treatment protocols targeting opioid use disorder and other substance dependencies; the company offers medicalized ibogaine therapy derived from the root bark of the iboga tree, which metabolizes into noribogaine to interrupt cravings and facilitate rapid detox; holistic recovery programs at its Kelburn Recovery Center near Winnipeg, Manitoba; clinical trial protocols advancing through Health Canada applications; and a global licensing model for ibogaine-enabled treatment clinics. Founded in 2017 and headquartered in Calgary, Alberta, Canada, Universal Ibogaine operates in the life sciences and behavioral health sectors, serving patients in North America with plans for international expansion through clinic acquisitions and protocol licensing. Recent developments include securing ibogaine drug supply and advancing a Clinical Trial Application with Health Canada in September 2025; appointing two new board members on September 3, 2025; closing the sale of its Belize property in January 2025; multiple private placement financings in 2024, including closings in June and April; and board and management changes, such as the CFO departure in July 2025 and debt settlements with the CEO.[investor news]
Universal Ibogaine provides Bi-weekly Default Status Report on 2025 year-end filings and update on Restructuring process
Universal Ibogaine provides Bi-weekly Default Status Report on 2025 year-end filings and update on Restructuring process
Universal Ibogaine Provides Bi-weekly Default Status Report on 2025 Year-end Filings and Update on Restructuring Process
Universal Ibogaine advises further on application for Management Cease Trade Order
Universal Ibogaine Advises of Filing Application for Management Cease Trade Order
Universal Ibogaine Provides Corporate Update
Universal Ibogaine Announces Board Changes
Universal Ibogaine Announces Results of the Annual Meeting of Shareholders
Universal Ibogaine Inc. provides update on intent to file Clinical Trial Application with Health Canada and confirms securing of Ibogaine drug supply
Universal Ibogaine advises of appointment of two new Board Members
Universal Ibogaine advises of departure of CFO
Universal Ibogaine Advises of Debt Settlement with CEO and Resignation of a Member of its Board of Directors
Universal Ibogaine Advises of Debt Settlement Agreement and Update on Status of Cease Trade Order
Universal Ibogaine says 2023 will be pivotal year for the company and Canadians seeking ibogaine treatment
Universal Ibogaine closes private placement, announces potential C$5M offering of convertible debt securities and shares
Universal Ibogaine forms advisory board in support of mission to deliver medicalized ibogaine-centered addiction care
Universal Ibogaine poised for offering to complete planned ibogaine-based clinical trial application
Universal Ibogaine says Kelburn addiction recovery clinic to reopen on October 17, 2022
Universal Ibogaine targets October re-opening of Kelburn addiction treatment facility near Winnipeg
Universal Ibogaine retains co-founder Shayne Nyquvest as capital markets advisor